Catalio Capital Management is a New York–based venture capital firm founded in 2020 by George C. Petrocheilos and R. Jacob Vogelstein, Ph.D. The firm focuses exclusively on healthcare and life sciences, supporting breakthrough biomedical technologies through venture, growth, credit, and public equity strategies. Since its launch, Catalio has made over 100 investments and distributed more than $300 million to limited partners. It operates globally with offices in New York, Washington D.C., and London.
Catalio invests across the healthcare and biotechnology spectrum, with particular focus on:
It partners with scientist-founders, university spin-outs, and emerging platforms working on transformative healthcare innovations.
Catalio Nexus Fund IV closed in mid-2025 with over $400 million in commitments, surpassing its original target. The fund has already invested in 16 companies and aims to support a total of 30 to 35 portfolio companies. Average check size is around $15 million.
Fund IV continues the firm’s thesis-driven approach, targeting innovations in drug discovery, diagnostics, and platform technologies. The capital comes from a mix of returning and new institutional limited partners, including foundations, endowments, and RIAs.
Catalio sees current market conditions (lower valuations, a quieter IPO environment, and accelerating biotech innovation) as a generational investment opportunity.
Leadership
Catalio is led by co-founders and Managing Partners George C. Petrocheilos and R. Jacob Vogelstein, Ph.D. The leadership team includes seasoned professionals across private and public investing, operations, and research. The firm’s Board of Advisors is chaired by Henry Kravis and includes figures such as Orlando Bravo, Glenn Dubin, Dina Powell McCormick, and Alex Gorsky. Catalio also collaborates with an extensive network of over 45 venture partners, including Nobel Prize winners and repeat scientific entrepreneurs.
Investment Strategy
Catalio’s investment strategy centers on identifying and backing transformational biomedical companies at all stages. The firm leverages its scientific expertise, clinical insight, and network of top-tier advisors to evaluate companies deeply. It maintains a flexible investment mandate across private and public markets and actively seeks to deploy capital during market dislocations. Catalio is highly focused on capital discipline and has returned distributions every year since its founding.
Notable Investments
Catalio’s recent investments include:
Notable Exits
Catalio has completed more than 20 exits since 2020. These include:
Other
Catalio manages approximately $1.9 to $2.0 billion in assets across its various strategies. In 2023, KKR acquired a minority stake in the firm and Henry Kravis became chairman of its advisory board. Catalio’s access to scientific talent and academic ecosystems, combined with its flexible capital model, makes it a unique player in the healthcare and biotech VC landscape.
